# Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

> **NCT05872724** · PHASE2 · RECRUITING · sponsor: **Suzhou Municipal Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab
- **DRUG:** Chemoradiotherapy (small pelvic) + Zimberelimab

## Key facts

- **NCT ID:** NCT05872724
- **Lead sponsor:** Suzhou Municipal Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-16
- **Primary completion:** 2028-01-16
- **Final completion:** 2028-12-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05872724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05872724, "Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05872724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*